重症COVID-19患者肺血管增殖:一项尸检研究
该尸检研究分析了16例重症COVID-19患者的肺组织,发现14例存在肾小球样微灶和/或融合性血管增殖(最大2cm),这些病变表达CD31、CD34和血管内皮钙黏蛋白,并伴有周细胞。血管改变可能参与重症COVID-19常见且难治性低氧血症的发生。
要点
- 重症COVID-19尸检肺组织常见肾小球样微灶和融合性血管增殖。
- 血管增殖病变表达CD31、CD34和血管内皮钙黏蛋白,并存在周细胞。
- 血管改变可能 contribute 于重症COVID-19的难治性低氧血症。
核心结论
- 重症COVID-19患者肺内存在肾小球样微灶和/或融合性血管增殖,可能参与严重难治性低氧血症。
研究设计与样本
- 尸检研究,纳入16例重症COVID-19患者肺组织。
主要发现
- 16例尸检患者中14例肺内存在肾小球样微灶和/或融合性血管增殖,病变最大达2cm。
- 血管增殖病变表达CD31、CD34和血管内皮钙黏蛋白。
- PDGFR-β免疫组化及CD34/平滑肌肌动蛋白双染显示存在周细胞。
临床怎么用
- 提示重症COVID-19难治性低氧血症需考虑肺血管增殖性改变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diffuse alveolar damage and thrombi are the most common lung histopathological lesions reported in patients with severe COVID-19. Although some studies have suggested increased pulmonary angiogenesis, the presence of vascular proliferation in COVID-19 lungs has not been well characterised. Glomeruloid-like microscopic foci and/or coalescent vascular proliferations measuring up to 2 cm were present in the lung of 14 out of 16 autopsied patients. These lesions expressed CD31, CD34 and vascular endothelial cadherin. Platelet-derived growth factor receptor-β immunohistochemistry and dual immunostaining for CD34/smooth muscle actin demonstrated the presence of pericytes. These vascular alterations may contribute to the severe and refractory hypoxaemia that is common in patients with severe COVID-19.
引用
- Pérez-Mies B, Gómez-Rojo M, Carretero-Barrio I, et al. Pulmonary vascular proliferation in patients with severe COVID-19: an autopsy study. Thorax. 2021. PMID: 33758071. doi:10.1136/thoraxjnl-2020-216714
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。